Community-associated methicillin-resistant Staphylococcus aureus and its emerging virulence

Modeling of Effective Antimicrobials to Reduce Staphylococcus aureus Virulence Gene Expression Using a Two-Compartment Hollow Fiber Infection Model

Toxins produced by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) contribute to virulence. We developed a statistical approach to determine an optimum sequence of antimicrobials to treat CA-MRSA infections based on an antimicrobial’s ability to reduce virulence. In an in vitro pharmacodynamic hollow fiber model, expression of six virulence genes (lukSF-PV, sek, seq, ssl8, ear, and lpl10) in CA-MRSA USA300 was measured by RT-PCR at six time points with or without human-simulated, pharmacokinetic dosing of five antimicrobials (clindamycin, minocycline, vancomycin, linezolid, and trimethoprim/sulfamethoxazole (SXT)). Statistical modeling identified the antimicrobial causing the greatest decrease in virulence gene expression at each time-point. The optimum sequence was SXT at T0 and T4, linezolid at T8, and clindamycin at T24–T72 when lukSF-PV was weighted as the most important gene or when all six genes were weighted equally. This changed to SXT at T0–T24, linezolid at T48, and clindamycin at T72 when lukSF-PV was weighted as unimportant. The empirical p-value for each optimum sequence according to the different weights was 0.001, 0.0009, and 0.0018 with 10,000 permutations, respectively, indicating statistical significance. A statistical method integrating data on change in gene expression upon multiple antimicrobial exposures is a promising tool for identifying a sequence of antimicrobials that is effective in sustaining reduced CA-MRSA virulence.

Phylogenetic distribution and expression of a penicillin-binding protein homologue, Ear and its significance in virulence of Staphylococcus aureus

PURPOSE

Staphylococcus aureus is an opportunistic human pathogen that can cause serious infections in humans. A plethora of known and putative virulence factors are produced by staphylococci that collectively orchestrate pathogenesis. Ear protein (Escherichia coli ampicillin resistance) in S. aureus is an exoprotein in COL strain, predicted to be a superantigen, and speculated to play roles in antibiotic resistance and virulence. The goal of this study was to determine if expression of ear is modulated by single nucleotide polymorphisms in its promoter and coding sequences and whether this gene plays roles in antibiotic resistance and virulence.

METHODOLOGY

Promoter, coding sequences and expression of the ear gene in clinical and carriage S. aureus strains with distinct genetic backgrounds were analysed. The JE2 strain and its isogenic ear mutant were used in a systemic infection mouse model to determine the competiveness of the ear mutant.Results/Key findings. The ear gene showed a variable expression, with USA300FPR3757 showing a high-level expression compared to many of the other strains tested including some showing negligible expression. Higher expression was associated with agr type 1 but not correlated with phylogenetic relatedness of the ear gene based upon single nucleotide polymorphisms in the promoter or coding regions suggesting a complex regulation. An isogenic JE2 (USA300 background) ear mutant showed no significant difference in its growth, antibiotic susceptibility or virulence in a mouse model.

CONCLUSION

Our data suggests that despite being highly expressed in a USA300 genetic background, Ear is not a significant contributor to virulence in that strain.

Performance of an electronic health record-based phenotype algorithm to identify community associated methicillin-resistant Staphylococcus aureus cases and controls for genetic association studies

Background

Community associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is one of the most common causes of skin and soft tissue infections in the United States, and a variety of genetic host factors are suspected to be risk factors for recurrent infection. Based on the CDC definition, we have developed and validated an electronic health record (EHR) based CA-MRSA phenotype algorithm utilizing both structured and unstructured data.

Methods

The algorithm was validated at three eMERGE consortium sites, and positive predictive value, negative predictive value and sensitivity, were calculated. The algorithm was then run and data collected across seven total sites. The resulting data was used in GWAS analysis.

Results

Across seven sites, the CA-MRSA phenotype algorithm identified a total of 349 cases and 7761 controls among the genotyped European and African American biobank populations. PPV ranged from 68 to 100% for cases and 96 to 100% for controls; sensitivity ranged from 94 to 100% for cases and 75 to 100% for controls. Frequency of cases in the populations varied widely by site. There were no plausible GWAS-significant (p < 5 E −8) findings.

Conclusions

Differences in EHR data representation and screening patterns across sites may have affected identification of cases and controls and accounted for varying frequencies across sites. Future work identifying these patterns is necessary.

Electronic supplementary material

The online version of this article (doi:10.1186/s12879-016-2020-2) contains supplementary material, which is available to authorized users.

Complex host genetic susceptibility to Staphylococcus aureus infections

Understanding of the host genetic susceptibility to carriage of, and infections, due to Staphylococcus aureus, a nosocomial pathogen, is still in its nascent stages. Mouse models show variable susceptibility to S. aureus infections across mouse strains and disease models with roles for signaling pathways involving Toll-like receptors (TLR-1, TLR-2, and TLR-6), interleukins (IL-4, IL-6, IL-10, and IL-13), chemokines [CXC ligand (CXCL)-1 and CXCL-2], and T helper (Th)1/Th2 responses. Genome-wide association studies (GWASs) for carriage in humans identified SNPs in IL4, DEFB1, CRP, and VDR for persistent nasal carriage. NR3C1 haplotypes may either enhance risk or provide protection from colonization. GWASs for all S. aureus diseases have suggested roles for DAPK3, a kinase, and XRN1, a nuclease, while CDON could have a role in complicated bacteremia. More studies are needed to identify host susceptibility genes along with confirmation from functional assays.

Potential risk for drug resistance globalization at the Hajj

Antibiotics were once considered the miracle cure for infectious diseases. The tragedy would be the loss of these miracles as we witness increased antibiotic resistance throughout the world. One of the concerns during mass gatherings is the transmission of antibiotic resistance. Hajj is one of the most common recurring mass gatherings, attracting millions of people from around the world. The transmission of drug-resistant organisms during the Hajj is not well described. In the current review, we summarize the available literature on the transmission and acquisition of antibiotic resistance during the Hajj and present possible solutions.

Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?

BACKGROUND

New data indicates that vancomycin may be less effective against methicillin-resistant Staphylococcus aureus (MRSA) infections with minimum inhibition concentration (MIC) within a sensitive range.

OBJECTIVES

The aim of this study was to determine the distribution of the vancomycin MIC between MRSA strains and observe the difference in mortality between patients, while the influence of changes in MIC on the efficacy of vancomycin was also examined.

PATIENTS AND METHODS

A routine date-based study was conducted on 41 MRSA isolates in a hospital in Tehran, Iran. The isolates were assessed for MIC by using the E-test method, and results were categorized into three groups: A (MIC < 1.5 μg/mL), B (1.5 ≤ MIC < 2 μg/mL) and C (MIC ≥ 2 μg/mL) MRSA.

RESULTS

Group A was the most common group, followed by groups C and B. Although there was no statistically significant difference between patients' mortality with the MIC group, the mortality rate of group A was higher than C and B.

CONCLUSIONS

Regarding Clinical and Laboratory Standards Institute (CLSI) definition for vancomycin susceptibility (MIC < 2 μg/mL), it seems that vancomycin may not be considered as the best antibiotic in order to treat heteroresistant vancomycin intermediate S. aureus (hVISA) and vancomycin sensitive S. aureus (VSSA) infections, and a new breakpoint for vancomycin and alternative antibiotics should be considered.

Update on management of skin and soft tissue infections in the emergency department

Skin and soft tissue infections (SSTIs) are frequently treated in the emergency department (ED) setting. Recent studies provide critical new information that can guide new approaches to the diagnosis and treatment of SSTIs in the ED. Rapid polymerase chain reaction assays capable of detecting MRSA in approximately 1 h hold significant potential to improving antibiotic stewardship in SSTI care. Emergency ultrasound continues to demonstrate value in guiding appropriate management of SSTIs, including the early diagnosis of necrotizing infections. Since emerging in the 1990s, community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) continues to increase in prevalence, and it represents a significant challenge to optimizing ED antibiotic use for SSTI management. Growing literature reinforces the current recommendation of incision and drainage without antibiotics for uncomplicated abscesses. Selecting antibiotics with CA-MRSA coverage is recommended when treating purulent SSTIs; however, it is generally not necessary in cases of nonpurulent cellulitis. Future advances in ED SSTI care may involve expansion of outpatient parenteral antimicrobial therapy protocols and the recent development of a novel, once weekly antibiotic with activity against MRSA.

Hospital-wide survey of bacterial contamination of point-of-care ultrasound probes and coupling gel

OBJECTIVES

The purpose of this study was to determine the hospital-wide incidence of bacterial contamination of point-of-care (bedside) ultrasound probes and coupling gel at a single academic medical center to predict the risk of nosocomial spread of infection.

METHODS

Bacterial cultures were performed on all point-of-care ultrasound probe surfaces and associated gel bottles in our institution (82 total probes in 9 separate departments). This process was repeated every 2 weeks for a total of 8 weeks; therefore, each probe was cultured 4 times during the study period.

RESULTS

Of the 320 probe cultures, 18 (5.6%), resulted in positive growth, all of which identified nonpathogenic organisms common to human skin flora and the environment. No methicillin-resistant Staphylococcus aureus or other notable pathogens were identified. No gel cultures resulted in bacterial growth.

CONCLUSIONS

Bacterial contamination of point-of-care ultrasound probes and coupling gel is low at this single academic medical center and involves nonpathogenic organisms only.

Treatment of infections due to resistant Staphylococcus aureus

This chapter reviews data on the treatment of infections caused by drug-resistant Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA). This review covers findings reported in the English language medical literature up to January of 2013. Despite the emergence of resistant and multidrug-resistant S. aureus, we have seven effective drugs in clinical use for which little resistance has been observed: vancomycin, quinupristin-dalfopristin, linezolid, tigecycline, telavancin, ceftaroline, and daptomycin. However, vancomycin is less effective for infections with MRSA isolates that have a higher MIC within the susceptible range. Linezolid is probably the drug of choice for the treatment of complicated MRSA skin and soft tissue infections (SSTIs); whether it is drug of choice in pneumonia remains debatable. Daptomycin has shown to be non-inferior to either vancomycin or β-lactams in the treatment of staphylococcal SSTIs, bacteremia, and right-sided endocarditis. Tigecycline was also non-inferior to comparator drugs in the treatment of SSTIs, but there is controversy about whether it is less effective than other therapeutic options in the treatment of more serious infections. Telavancin has been shown to be non-inferior to vancomycin in the treatment of SSTIs and pneumonia, but has greater nephrotoxicity. Ceftaroline is a broad-spectrum cephalosporin with activity against MRSA; it is non-inferior to vancomycin in the treatment of SSTIs. Clindamycin, trimethoprim-sulfamethoxazole, doxycycline, rifampin, moxifloxacin, and minocycline are oral anti-staphylococcal agents that may have utility in the treatment of SSTIs and osteomyelitis, but the clinical data for their efficacy is limited. There are also several drugs with broad-spectrum activity against Gm-positive organisms that have reached the phase II and III stages of clinical testing that will hopefully be approved for clinical use in the upcoming years: oritavancin, dalbavancin, omadacycline, tedizolid, delafloxacin, and JNJ-Q2. Thus, there are currently many effective drugs to treat resistant S. aureus infections and many promising agents in the pipeline. Nevertheless, S. aureus remains a formidable adversary, and despite our deep bullpen of potential therapies, there are still frequent treatment failures and unfortunate clinical outcomes. The following discussion summarizes the clinical challenges presented by MRSA, the clinical experience with our current anti-MRSA antibiotics, and the gaps in our knowledge on how to use these agents to most effectively combat MRSA infections.

G. Nosocomial Infections and Drug Susceptibility Patterns in Methicillin Sensitive and Methicillin Resistant Staphylococcus aureus

AIM

Staphylococcus aureus is one of the leading causes of nosocomial infections and is known for its ability to develop resistance to antibiotics. The drug susceptibility pattern of Methicillin Sensitive S. aureus (MSSA) and Methicillin Resistant S. aureus (MRSA) may vary. AIMs and Objectives: This study was carried out to determine and compare the drug susceptibility patterns in nosocomial MSSA and MRSA.

MATERIAL AND METHODS

The study was conducted between September 2009 and August 2011. Standard conventional methods were used for the isolation and identification of S. aureus. MRSA was identified by the cefoxitin (30 μg) disk method. Antibiotic susceptibility test was done using Kirby-Bauer disk diffusion method and the interpretation of the results was done using CLSI guidelines.

RESULTS

Out of 685 strains of S. aureus studied, 173(25.25%) were MRSA and 512 (74.25%) were MSSA. Out of 173 MRSA strains, 114(65.89%) were isolated from pus, 22(12.71%) from vaginal swab, 18(10.40%) from central catheter tip and the remaining from other specimens. All isolates were susceptible to vancomycin and least number of isolates were susceptible to penicillin. MRSA displayed significantly higher resistance to other antibiotics. 45.7% of MRSA strains were resistant to clindamycin, 64.7% to ciprofloxacin, 87.3% to cotrimoxazole, 54.3% to erythromycin, 17.3% to gentamicin, 16.8% to netilmycin, and 58.38% to tetracycline. Inducible clindamycin resistance was detected in 37 (21.38%) strains of MRSA.

CONCLUSION

Nosocomial infections caused by MRSA is a significant problem. MRSA and MSSA differ with their susceptibility to antibiotics. All MRSA isolates in our hospitals were susceptible to vancomycin. Proper selection of the antibiotics based on antibiotic susceptibility test results is needed for effective treatment and prevention of emergence of resistance in MRSA and MSSA.

Naturally occurring IgG antibody levels to the Staphylococcus aureus protein IsdB in humans

Staphylococcus aureus is a well-recognized, clinically important cause of nosocomial infections, and as such, a vaccine to prevent S. aureus infections would be an important achievement. A Phase IIB/III study of V710, a vaccine containing iron-regulated surface determinant B (IsdB), demonstrated significant sero-conversion rates in cardiovascular surgery patients following a single pre-surgery immunization. However, the vaccine was not efficacious in preventing bacteremia or deep sternal wound infection post-surgery, thus raising the possibility that IsdB might not be available for immune recognition during infection. The purpose of the work described herein was to evaluate and quantify the naturally occurring anti-IsdB levels at baseline and over time during infection, to understand whether IsdB is expressed during a S. aureus infection in hospitalized non-vaccinated patients. We evaluated baseline and follow-up titers in 3 populations: (1) healthy subjects, (2) hospitalized patients with non-S. aureus infections, and (3) hospitalized patients with S. aureus infections. Baseline anti-IsdB levels generally overlapped between the 3 groups, but were highly variable within each group. In healthy subjects, baseline and follow-up levels were highly correlated (Spearman's rho = 0.93), and the geometric mean fold-rise (GMFR) in anti-IsdB levels between study entry and last value was 0.9-fold (95% confidence interval (CI): 0.8 to 1.0 ; p = 0.09), showing no trend over time. The convalescent GMFR in anti-IsdB levels from baseline was 1.7-fold (95% CI: 1.3 to 2.2, p = 0.0008) during S. aureus infection, significantly different from the 1.0-fold GMFR (95% CI: 0.9-1.2, p = 0.60) in non-S. aureus infection, p = 0.005. Additionally, S. aureus isolates (51) obtained from the hospitalized patient group expressed the IsdB protein in vitro. Collectively, these data suggest that IsdB expression levels rise substantially following infection with S. aureus, but not with other pathogens, and IsdB is likely well-conserved across S. aureus strains.

Clinical features and risk factors of mortality for bacteremia due to community-onset healthcare-associated methicillin-resistant S. aureus

Studies comparing adult community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) and community-onset healthcare-associated MRSA (COHCA MRSA bacteremia have not been available. From 1 January 2010 through 30 October 2010, a prospective observational program was conducted among all patients aged >16 years with positive Staphylococcus aureus blood cultures within 48 h after their arrival at the emergency department of our hospital. Clinical course of infection and infection foci of bacteremia were evaluated. Resistance to oxacillin was confirmed with the presence of mecA gene examined by polymerase chain reaction. Presence of TSST-1, PVL gene, SCCmec elements (I-V), mecA gene, and multilocus sequence typing were identified through methods described elsewhere. Univariate and multivariate analysis revealed that chronic renal failure was significantly more common in COHCA-MRSA than in CA-MRSA. In addition, APACHE III score was significantly higher in COHCA-MRSA than in CA-MRSA. Both the 7-day and 30-day mortality rates in COHCA-MRSA, 14.6% (7/48) and 29.2% (14/48), respectively, were higher than those in CA-MRSA without a significant difference. SCCmec II was more common in COHCA-MRSA, but SCCmecVT was more common in CA-MRSA. The majority of MRSA isolates belonged to ST59, ST239, and ST5. ST59 was significantly more common in CA-MRSA, while ST239 was nearly equally common in both CA-MRSA and COHCA-MRSA. SCCmec III and II isolates were the first and second most resistant to the antibiotics commonly used for S. aureus, whereas SCCmecVT isolates were the most susceptible to these antibiotics. We conclude that, although both CA-MRSA and COHCA-MRSA bacteremia had community onset, these 2 MRSA infections were different in underlying diseases, risk of mortality, SCCmec types, sequence types, and antimicrobial susceptibility. It is more appropriate to understand the MRSA pathogen and clinical features based on etiology and ST types than based on the location of disease onset. CA-MRSA and HCA-MRSA should be differentiated also based on etiology and ST types, in addition to location of acquisition.

Comparative whole-genome mapping to determine Staphylococcus aureus genome size, virulence motifs, and clonality

Despite being a clonal pathogen, Staphylococcus aureus continues to acquire virulence and antibiotic-resistant genes located on mobile genetic elements such as genomic islands, prophages, pathogenicity islands, and the staphylococcal chromosomal cassette mec (SCCmec) by horizontal gene transfer from other staphylococci. The potential virulence of a S. aureus strain is often determined by comparing its pulsed-field gel electrophoresis (PFGE) or multilocus sequence typing profiles to that of known epidemic or virulent clones and by PCR of the toxin genes. Whole-genome mapping (formerly optical mapping), which is a high-resolution ordered restriction mapping of a bacterial genome, is a relatively new genomic tool that allows comparative analysis across entire bacterial genomes to identify regions of genomic similarities and dissimilarities, including small and large insertions and deletions. We explored whether whole-genome maps (WGMs) of methicillin-resistant S. aureus (MRSA) could be used to predict the presence of methicillin resistance, SCCmec type, and Panton-Valentine leukocidin (PVL)-producing genes on an S. aureus genome. We determined the WGMs of 47 diverse clinical isolates of S. aureus, including well-characterized reference MRSA strains, and annotated the signature restriction pattern in SCCmec types, arginine catabolic mobile element (ACME), and PVL-carrying prophage, PhiSa2 or PhiSa2-like regions on the genome. WGMs of these isolates accurately characterized them as MRSA or methicillin-sensitive S. aureus based on the presence or absence of the SCCmec motif, ACME and the unique signature pattern for the prophage insertion that harbored the PVL genes. Susceptibility to methicillin resistance and the presence of mecA, SCCmec types, and PVL genes were confirmed by PCR. A WGM clustering approach was further able to discriminate isolates within the same PFGE clonal group. These results showed that WGMs could be used not only to genotype S. aureus but also to identify genetic motifs in MRSA that may predict virulence.

Survival and transmission of community-associated methicillin-resistant Staphylococcus aureus from fomites

BACKGROUND

Transmission of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) from fomites appears to play an important role in CA-MRSA outbreaks. However, the amount and duration of transmissibility of MRSA have not been quantified.

METHODS

We assessed the survival and transmission of the CA-MRSA strain USA300-0114 from 9 fomites (razors, plastic toys, ceramic, soap, wood, vinyl, towels, bed sheets, and shoulder pads). Fomites were inoculated then briefly pressed onto sterile pigskin at 5 minutes; days 1, 2, 3, 7, and 10; and then weekly for 10 weeks. The experiment was repeated using 2 methicillin-susceptible S aureus (MSSA) and 3 health care-associated (HA) MRSA strains on select fomites.

RESULT

Bacteria could be transmitted to skin from all fomites except soap. Transmissibility decreased over time but more rapidly from porous (eg, towels) than nonporous (eg, vinyl) fomites (P = .0002), with some fomites showing transmissibility for more than 8 weeks after contamination. The CA-MRSA strain was transmissible longer than the HA-MRSA strains (P < .0001) and 1 MSSA strain.

CONCLUSION

CA-MRSA strains are transmissible from many fomites to skin with contaminated nonporous fomites exhibiting transmissibility many weeks after contamination. Transmissibility of HA-MRSA strains demonstrated attenuated transmissibility compared with CA-MRSA strains. Findings may have implications for CA-MRSA infection prevention.

Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci

Solithromycin (CEM-101) is a novel fluoroketolide with high potency against Gram-positive and Gram-negative bacteria commonly associated with community-acquired respiratory tract infections and skin and skin-structure infections. In this study, solithromycin and comparator antimicrobials were tested against a contemporary collection of Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, Enterococcus faecium and other Enterococcus spp. collected in the SENTRY Antimicrobial Surveillance Program. Solithromycin was active against S. aureus [minimum inhibitory concentration for 50% of the organisms (MIC(50))=0.12 μg/mL] and was two-fold more active than telithromycin (MIC(50)=0.25 μg/mL). Solithromycin was more potent against methicillin (oxacillin)-susceptible S. aureus [MIC(50)=0.06 μg/mL and MIC for 90% of the organisms (MIC(90))=0.12 μg/mL) compared with methicillin (oxacillin)-resistant S. aureus (MIC(50)=0.12 μg/mL and MIC(90)>16 μg/mL). Solithromycin activity was reduced amongst heterogeneous vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus (MIC(50)>16 μg/mL). Against strains with defined susceptibilities to erythromycin, clindamycin and telithromycin, solithromycin showed potent inhibition against all combinations (MIC(50)=0.06 μg/mL) except those with non-susceptibility to telithromycin (>2 μg/mL) (MIC(50)>16 μg/mL). The solithromycin MIC(50) for E. faecium (1 μg/mL) was four-fold higher than the MIC(50) for E. faecalis (0.25 μg/mL). In summary, solithromycin demonstrated high potency against many Staphylococcus and Enterococcus spp. isolated from contemporary infections worldwide.

Post-surgical wound infections involving Enterobacteriaceae with reduced susceptibility to β-lactams in two Portuguese hospitals

The post-surgical period is often critical for infection acquisition. The combination of patient injury and environmental exposure through breached skin add risk to pre-existing conditions such as drug or depressed immunity. Several factors such as the period of hospital staying after surgery, base disease, age, immune system condition, hygiene policies, careless prophylactic drug administration and physical conditions of the healthcare centre may contribute to the acquisition of a nosocomial infection. A purulent wound can become complicated whenever antimicrobial therapy becomes compromised. In this pilot study, we analysed Enterobacteriaceae strains, the most significant gram-negative rods that may occur in post-surgical skin and soft tissue infections (SSTI) presenting reduced β-lactam susceptibility and those presenting extended-spectrum β-lactamases (ESBL). There is little information in our country regarding the relationship between β-lactam susceptibility, ESBL and development of resistant strains of microorganisms in SSTI. Our main results indicate Escherichia coli and Klebsiella spp. are among the most frequent enterobacteria (46% and 30% respectively) with ESBL production in 72% of Enterobacteriaceae isolates from SSTI. Moreover, coinfection occurred extensively, mainly with Pseudomonas aeruginosa and Methicillin-resistant Staphylococcus aureus (18% and 13%, respectively). These results suggest future research to explore if and how these associations are involved in the development of antibiotic resistance.

Treatment of Methicillin-Resistant Staphylococcus Aureus with a Vancomycin Minimum Inhibitory Concentration of 2 mcg/mL

Background

Vancomycin has been considered the standard of therapy for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) for decades. The aims of this study were to describe the clinical outcomes of patients with infections caused by MRSA with a vancomycin minimum inhibitory concentration (MIC) of 2 mcg/mL and determine whether achievement of a high vancomycin trough concentration affected outcomes.

Methods

A retrospective analysis was conducted on data from a single medical center from 2003 through 2007. The study included patients with a culture positive for MRSA with a vancomycin MIC of 2 mcg/mL who received vancomycin therapy. Treatment groups were determined by weighted average vancomycin trough concentration. Subjects were assigned to either the conventional (less than 15 mcg/mL) or high (15 mcg/mL or higher) trough group. Outcome measures included attainment of clinical cure, all-cause mortality, and occurrence of nephrotoxicity.

Results

Of the 79 patients included in the study, 50 (63.3%) attained clinical cure. Rate of clinical cure was similar between the conventional and high trough groups (64.7% vs 60.7%, P = 0.7). Treatment arms were similar in regard to all-cause mortality and other secondary endpoints. Patients demonstrating clinical response at 72 hours were significantly more likely to progress to clinical cure than those continuing to show signs of infection (77.8% vs 32.5, P < 0.001).

Conclusions

Use of vancomycin for the treatment of MRSA with a vancomycin MIC of 2 mcg/mL resulted in a low rate of clinical cure. Data from this study suggest that achieving higher vancomycin trough concentrations is not a sufficient strategy for enhancing efficacy in these challenging infections.

The prevalence of methicillin-resistant Staphylococcus aureus on inanimate objects in an Urban Emergency Department

BACKGROUND

There is a rising prevalence of both hospital-acquired and community-associated strains of methicillin-resistant Staphylococcus aureus (MRSA) infections. Both strains are found in patients presenting to emergency departments (EDs).

OBJECTIVE

The purpose of this study was to identify objects in the ED that might contribute to the spread of MRSA.

METHODS

This was a cross-sectional prevalence study in which culture swabs were taken from 20 different objects in a large urban ED between May and August 2006. The objects were identified a priori, and included common items found in an ED. Items ranging from computers to telephones, desktop surfaces, security door keypads, and ultrasound probes were included in the study. Each item was cultured twice, on separate days, for a total of 40 samples. The samples were screened for the presence of MRSA, and positive samples underwent additional susceptibility analysis.

RESULTS

Only one sample of 40, from the ambulance bay security door keypad, was positive for MRSA. Thus, the prevalence of MRSA was 2.5%. The single strain isolated was resistant to clindamycin, erythromycin, oxacillin, and penicillin.

CONCLUSION

MRSA does not seem to thrive on inanimate objects found in the ED. Routine cleaning measures in an urban ED must include all areas of medical personnel use, including areas outside of the department utilized by non-ED workers.

Preventing Community-Associated Methicillin-Resistant Staphylococcus aureus Among Student Athletes

Methicillin-resistant Staphylococcus aureus (MRSA) was once thought to be a bacterium causing infections in only hospitalized patients. However, a new strain of MRSA has emerged among healthy individuals who have not had any recent exposure to a hospital or to medical procedures. This new strain is known as community-associated MRSA. Studies have shown the rates of MRSA infection are increasing throughout the United States and that some populations are at greater risk of acquiring these infections. One population at greater risk is athletes. Educating student athletes, parents, coaches, and administrators about the seriousness of this infection and how to prevent and manage it in the school setting is an important role of the school nurse. The goal of this education is to prevent the spread of MRSA organisms, thereby reducing student absenteeism and the related costs of treating MRSA infections.

Management and Treatment Considerations for Infections Caused by Methicillin-Resistant Staphylococcus aureus

Infections caused by methicillin-resistant Staphylococcus aureus have been documented since the 1960s. Four decades later, this microorganism has evolved from a pathogen found primarily in the health care environment to a major pathogen of community-acquired infections. Interestingly, the community-acquired methicillin-resistant Staphylococcus aureus isolates tend to be genetically distinct from their health-care–acquired relatives, have a propensity to be more virulent, yet be susceptible to more antibiotics. Furthermore, infections caused in the pediatric population have a susceptibility pattern that differs from those found in adults. With an increase in infections caused by methicillin-resistant Staphylococcus aureus, empiric therapy should contain an agent with activity against this microorganism. Currently several options exist for the treatment of skin and skin structure infections, yet very few options are available for the treatment of more invasive diseases caused by methicillin-resistant Staphylococcus aureus. This article will review the history of methicillin-resistant Staphylococcus aureus, Staphylococcus aureus economic considerations, and the current plus future treatment options for these infections.

MRSA-related perianal abscesses: an underrecognized disease entity

PURPOSE

Methicillin-resistant Staphylococcus aureus (MRSA) in perianal abscesses represents an underrecognized condition. It is unclear whether these abscesses differ in presentation or other characteristics from their non-MRSA counterparts.

METHODS

Patients diagnosed with perianal abscess, who underwent incision and drainage between January 2003 and September 2005, were identified retrospectively. Demographics, abscess characteristics (induration, erythema, abscess size, amount of purulence), presence of MRSA on culture, MRSA susceptibilities, and clinical course were collected.

RESULTS

A total of 104 patients (62.5 percent male; mean age, 42.7+/-13.7 years) were treated for perianal abscess. For the 69 patients cultured at drainage, MRSA was present in 34.8 percent (24/69) of cases (95 percent confidence interval, 24.6-46.6 percent). MRSA-positive patients did not significantly differ from MRSA-negative patients with respect to age, MRSA risk factors, duration of symptoms, white blood cell count at admission, or length of stay. Patients were more likely to be MRSA-positive if they possessed extensive induration (odds ratio, 6.52; P=0.003), extensive erythema (odds ratio, 5.75; P=0.003), or small amount of purulence (odds ratio, 9.72; P=0.006). Ischiorectal abscesses were significantly less likely to be MRSA-positive (odds ratio, 0.34; P=0.016). No patients with MRSA-positive abscesses developed fistulas. All MRSA isolates were resistant to beta-lactam antibiotics and had limited susceptibility to quinolones.

CONCLUSIONS

The prevalence of MRSA in perianal abscesses has not been described previously and is higher in our group of patients than would be expected. MRSA-positive patients cannot be identified by risk factors alone. Antibiotic resistance spectra of MRSA vary from that of enteric bacteria typically seen in perianal abscesses. Therefore, it may be beneficial to culture all perianal abscesses with extensive induration and erythema or minimal purulence.

Sporadic "transitional" community-associated methicillin-resistant Staphylococcus aureus strains from health care facilities in the United States

We describe phenotypic and genotypic traits of a group of methicillin-resistant Staphylococcus aureus (MRSA) clones that are either remnants of unsuccessful community-associated MRSA (CA-MRSA) clones or represent a transitional state with some yet-to-be-acquired characteristics of CA-MRSA. These rare strains (n = 20) were identified during a 10-year period (1990-1999) from 13 unrelated health care facilities in Wisconsin. The isolates were recovered from patients in nosocomial or long-term chronic care facilities (60%) and outpatient settings (40%). Sixty percent (n = 12) of the isolates were recovered from skin and soft tissue infections, whereas the remaining isolates (n = 8) were from invasive infections. Ninety percent of isolates were susceptible to all antibiotic classes tested or resistant to erythromycin and clindamycin. Pulsed-field gel electrophoresis, multilocus sequence typing, and spa typing clustered these isolates into 8, 8, and 14 clonal groups, respectively. Eight plasmid profiles were represented in these strains. All four agr types were represented, with type IV being predominant (40%). All strains harbored subtypes of type IV staphylococcal cassette chromosome mec but lacked genes for the virulence factor Panton-Valentine leukocidin (PVL). The strains harbored one or more of the following toxin genes: sea, seb, sec, sed, see, seh, sej, sek, sel, seg, sei, sem, sen, and seo. Individual clonal groups maintained the same set of enterotoxin genes even though they were isolated over extended time periods, suggesting significant genomic stability. The potential role of PVL-carrying phages and plasmids in the success of CA-MRSA clones has been discussed.

Treatment of infections caused by resistant Staphylococcus aureus

We review data on the treatment of infections caused by drug-resistant Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA). In this review, we cover findings reported in the English language medical literature up to February 2006. Despite the emergence of resistant and multidrug resistant S. aureus, five effective drugs for which little resistance has been observed are in clinical use: vancomycin, quinupristin-dalfopristin, linezolid, tigecycline, and daptomycin. However, vancomycin is less effective for infections with MRSA isolates that have a high minimum inhibitory concentration in the susceptible range. Linezolid looks promising in the treatment of MRSA pneumonia and skin and soft-tissue infections (SSTIs). Daptomycin displays rapid bactericidal activity in vitro, and it has been shown to be noninferior to comparator agents in the treatment of SSTIs and bacteremia. Tigecycline was also noninferior to comparator drugs in the treatment of SSTIs. Clindamycin, trimethoprim-sulfamethoxazole, doxycycline, and minocycline are oral antistaphylococcal agents that may have utility in the treatment of SSTIs and osteomyelitis, but the clinical data for their efficacy is limited. There are four drugs with broad-spectrum activity against Gram-positive organisms at an advanced stage of clinical testing: ceptobiprole and three new glycopeptides with potent bactericidal activity, oritavancin, dalbavancin, and telavancin. Thus, there are currently many effective drugs to treat resistant S. aureus infections and many promising agents in the pipeline. Nevertheless, S. aureus remains a formidable adversary against which there are frequent treatment failures. The next goals are to determine the most appropriate indications and cost-effectiveness of each of these drugs in the treatment strategy against S. aureus.

Shift in Staphylococcus aureus clone linked to an infected tattoo

A retrospective investigation of skin and soft tissue infections caused by community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains among inmates in a Wisconsin correctional facility suggested a shift in MRSA genotype. Case timeline indicated a displacement of USA400 clone by USA300 clone. The USA300 index case was associated with an infected new tattoo.

[Direct and fast detection of methicillin resistant Staphylococcus aureus carriage by automated nucleic acid extraction and real time PCR]

We have developed a real time PCR assay for methicillin resistant Staphylococcus aureus (MRSA) screening able to provide a result in less than 3 h. The PCR amplifies a 184 bp fragment corresponding to the junction area between mecA and orfX genes that allows specific identification of MRSA in a nonsterile specimen. 1481 nasal swabs taken from geriatrics, dialysis and intensive care patients were compared with traditional bacteriology. A short centrifugation, preliminary to the extraction, with "SETS" system allows a recovery of the sample. The automated DNA extraction is carried out by the MagNA Pure LC and the PCR by the LightCycler. The agreement between the two methods is 97.7%. A study of sensitivity and specificity on 1111 samples respectively gives 75 and 98% for the real time PCR and, 64 and 99% for the culture. The strategy of fast and effective tracking that we propose is of an undeniable contribution in the fight against the MRSA infections.

The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus (MRSA) is well-recognised as a major cause of infection in the health care setting but, even more worryingly, is now emerging in the community. The glycopeptides-notably vancomycin-have traditionally been the mainstay of treatment of MRSA but overuse has led to the emergence of vancomycin-intermediate and vancomycin-resistant MRSA (VISA and VRSA, respectively). Although the mechanisms underlying vancomycin resistance are not yet fully understood, changes to the bacterial cell wall-the site of action of the glycopeptides-are believed to be key. Recent evidence also supports the transfer of genetic material among bacteria as contributing to the development of VRSA. Based on the cases identified to date, risk factors for the development of VRSA may include older age, compromised blood flow to the lower limbs, and the presence of chronic ulcers. The true extent of the problem, however, remains to be determined-it is likely that many cases of VISA and VRSA infection go undetected because of suboptimal screening programmes and possible limitations of automated and non-automated detection methods. Effective screening directed at those patients considered to be most at risk should therefore be a priority. Not surprisingly, the spread of MRSA from the hospital to the community setting, coupled with the emergence of VISA and VRSA, has become a major cause of concern among clinicians and microbiologists. The treatment options available for these infections are now severely compromised and thus new classes of antimicrobial agents effective against MRSA, VISA and VRSA are urgently required.